
AstraZeneca beefs up cell therapy tool kit with gene editing deal
AstraZeneca is licensing Revvity’s gene-editing technology in a non-exclusive agreement for an undisclosed amount in order to create cell therapies for the treatment of cancer and immune-mediated diseases, Revvity said Thursday.
AstraZeneca is licensing the technology underlying Revvity’s base editing system, dubbed Pin-point. It’s designed to edit genes “without unintended impact on cell viability or functionality.” Revvity says that unlike CRISPR, which creates double-stranded DNA breaks, their editing system uses a modified Cas enzyme that only “nicks” one strand of the DNA.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters